A Case Report of Severe Bradycardia Associated With Nirmatrelvir-ritonavir Drug-drug Interactions

被引：0

作者：

Fu, Zhiqing ^{[1
,2
]}

Guo, Yan ^{[1
,2
]}

Li, Shuai ^{[1
,2
]}

Shi, Yang ^{[1
,2
]}

机构：

[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 2, Dept Cardiol, Beijing 100853, Peoples R China

[2] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing 100853, Peoples R China

来源：

CARDIOLOGY DISCOVERY | 2025年 / 5卷 / 01期

关键词：

Bradycardia; Nirmatrelvir-ritonavir; Drug interactions; Elderly; Case report; IVABRADINE;

D O I：

10.1097/CD9.0000000000000150

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

With the increasing use of nirmatrelvir-ritonavir in older COVID-19 patients, adverse drug reactions due to drug-drug interactions have become more frequent. This report describes a patient who experienced severe bradycardia and hypotension following the concurrent use of heart rate-control medications and nirmatrelvir-ritonavir during an active COVID-19 infection. This suggests that clinicians should be cautious when dealing with nirmatrelvir-ritonavir and try their best to avoid serious adverse reactions.

引用

页码：91 / 93

页数：3

共 50 条

[31] Response to Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
Morganne Sindelar
Daniel McCabe
Elisabeth Carroll
Journal of Medical Toxicology, 2023, 19 : 309 - 309
[32] Response to Comment on "Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin"
Sindelar, Morganne
McCabe, Daniel
Carroll, Elisabeth
JOURNAL OF MEDICAL TOXICOLOGY, 2023, 19 (03) : 309 - 309
[33] Pharmacokinetics of nirmatrelvir/ritonavir and the drug-drug interaction with calcineurin inhibitor in renal transplant recipients
Xu, Xueyin
Zhang, Huanxi
Liu, Longshan
Fu, Qian
Wu, Chenglin
Lin, Xiaobin
Tang, Kejing
Wang, Changxi
Chen, Pan
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (08) : 1219 - 1227
[34] Pharmacist's role in the management of drug-drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients
Cordero, Carlos Guzman
de Vicente, Maria Saez-Torres
Espinosa, Alvaro Jimenez
Sanchez, Ana Isabel Gago
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
[35] Nirmatrelvir+ritonavir/paracetamol/tacrolimusVarious toxicity and tacrolimus toxicity following drug interactions: case report
Reactions Weekly, 2023, 1963 (1) : 416 - 416
[36] Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer
Anwar, Kaleem
Nguyen, Lee
Nagasaka, Misako
Ou, Sai-Hong Ignatius
Chan, Alexandre
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02):
[37] Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions
Paul Hollywood
Rachel MacCann
David Lorigan
Eoghan de Barra
Samuel McConkey
Irish Journal of Medical Science (1971 -), 2020, 189 : 693 - 699
[38] Management of drug-related problems including drug-drug interactions caused by nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2
Yalcin, Nadir
Demirkan, Kutay
ARCHIVES OF DISEASE IN CHILDHOOD, 2023, 108 (10)
[39] Pharmacokinetic enhancers (cobicistat/ritonavir) and the potential for drug-drug interactions
Hollywood, Paul
MacCann, Rachel
Lorigan, David
de Barra, Eoghan
McConkey, Samuel
IRISH JOURNAL OF MEDICAL SCIENCE, 2020, 189 (02) : 693 - 699
[40] Nirmatrelvir+ritonavir/venlafaxine interactionHyponatraemia following drug interaction: case report
Reactions Weekly, 2023, 1943 (1) : 544 - 544

← 1 2 3 4 5 →